1,314,229 Shares in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Purchased by BML Capital Management LLC

BML Capital Management LLC bought a new stake in shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,314,229 shares of the company's stock, valued at approximately $2,103,000. Reneo Pharmaceuticals makes up 1.6% of BML Capital Management LLC's holdings, making the stock its 14th biggest position. BML Capital Management LLC owned 3.95% of Reneo Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of RPHM. Bank of New York Mellon Corp boosted its position in shares of Reneo Pharmaceuticals by 13.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 35,963 shares of the company's stock valued at $274,000 after purchasing an additional 4,165 shares during the period. Barclays PLC lifted its stake in Reneo Pharmaceuticals by 5.7% in the 3rd quarter. Barclays PLC now owns 78,118 shares of the company's stock worth $595,000 after acquiring an additional 4,244 shares in the last quarter. Dorsey Wright & Associates purchased a new stake in Reneo Pharmaceuticals in the 3rd quarter worth about $28,000. Pale Fire Capital SE purchased a new stake in Reneo Pharmaceuticals in the 3rd quarter worth about $113,000. Finally, Eventide Asset Management LLC lifted its stake in Reneo Pharmaceuticals by 18.8% in the 3rd quarter. Eventide Asset Management LLC now owns 2,078,142 shares of the company's stock worth $15,825,000 after acquiring an additional 328,142 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company's stock.

Reneo Pharmaceuticals Stock Performance

Reneo Pharmaceuticals stock remained flat at $1.68 during mid-day trading on Wednesday. The company had a trading volume of 138,349 shares, compared to its average volume of 274,945. The stock's 50-day moving average is $1.66 and its 200 day moving average is $3.50. The firm has a market cap of $56.15 million, a P/E ratio of -0.67 and a beta of 0.24. Reneo Pharmaceuticals, Inc. has a 1 year low of $0.98 and a 1 year high of $10.98.

Reneo Pharmaceuticals (NASDAQ:RPHM - Get Free Report) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.15). As a group, equities analysts forecast that Reneo Pharmaceuticals, Inc. will post -0.85 earnings per share for the current fiscal year.

Reneo Pharmaceuticals Company Profile

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.